Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype.
Blum
Shany
S
Milman
Uzi
U
Shapira
Chen
C
Miller-Lotan
Rachel
R
Bennett
Lawrence
L
Kostenko
Maria
M
Landau
Michele
M
Keidar
Shlomo
S
Levy
Yishai
Y
Khemlin
Alexander
A
Radan
Arman
A
Levy
Andrew P
AP
D000367:Age Factors; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics*; D004359:Drug Therapy, Combination; D005260:Female; D005819:Genetic Markers; D005838:Genotype; D006242:Haptoglobins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012016:Reference Values; D018570:Risk Assessment; D012737:Sex Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014810:Vitamin E / Q000627:therapeutic use*
D000975:Antioxidants; D005819:Genetic Markers; D006242:Haptoglobins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014810:Vitamin E